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Abstract
Background: Human pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal
malignancies in the world and despite great efforts in research types of treatment remain limited. A frequently
detected alteration in PDACs is a truncated O-linked N-acetylgalactosamine (GalNAc) glycosylation with expression
of the Tn antigen. Changes in O-glycosylation affect posttranslationally modified O-GalNAc proteins resulting in
profound cellular alterations. Tn antigen is a tumor associated glycan detected in 75-90 % of PDACs and up to 67 %
in its precursor lesions. Since the role of Tn antigen expression in PDAC is insufficiently understood we analyzed the
impact of COSMC mediated Tn antigen expression in two human PDAC cell lines on cellular oncogenic properties.
Methods: Forced expression of Tn antigen on O-glycosylated proteins in pancreatic cancer cells was induced by
lentiviral-mediated knockdown of the COSMC chaperone, which prevented O-glycan elongation beyond the initial
GalNAcα1- residue on O-linked glycoproteins. Altered O-GalNAc glycosylation was analyzed in human pancreatic cancer
cell lines Panc-1 and L3.6pl using Western and Far-Western blot as well as immunocytochemical techniques. To assess
the biological implications of COSMC function on oncogenic properties, cell viability assays, scratch assays combined
with live cell imaging, migration and apoptosis assays were performed. Lectin based glycoprotein enrichment with
subsequent mass spectrometric analysis identified new cancer O-GalNAc modified proteins. Expression of Tn antigen
bearing Nucleolin in patient derived PDAC tumor specimens was evaluated and correlated with clinicopathological data.
Results: Tn antigen expression was induced on various O-GalNAc glycoproteins in COSMC deficient cell lines
compared to the control. Proliferation was reduced (p < 0.001) in COSMC knockdown cells, whereas migration was
increased (p < 0.001) and apoptosis was decreased (p = 0.03), highlighting the importance of Tn antigen expression
on metastatic and anti-apoptotic behavior of PDAC derived cells. Nucleolin was identified as O-GalNAc modified
protein in COSMC deficient PDAC cell lines. Interestingly, immunohistochemical staining and co-localization studies
of patient derived PDACs revealed poor survival for patients with strong co-localization of Tn antigen and Nucleolin
(p = 0.037).
Conclusion: This study substantiates the influence of altered O-glycan (Tn/STn) expression on oncogenic properties in
pancreatic cancer and identifies O-GalNAc modified Nucleolin as novel prognostic marker.
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Background
Changes in O-GalNAc glycosylation (N-acetylgalactosa-
minyl glycosylation; hereafter referred simply as O-
glycosylation) are typical characteristics of malignant
transformation in epithelial cells [1]. Given the complex-
ity of protein glycosylation and its superordinated im-
pact on a diverse range of biological processes it is not
surprising that seemingly minor alterations in carbohy-
drate structure can significantly impact cell biology.
Current research on differential O-glycosylation starts to
elucidate its influence on carcinogenesis and malignant
transformation. For instance, O-glycosylation of DR4/DR5
death receptor regulates apoptosis resistance or sensitivity
[2] and aberrant O-glycosylation of β-integrins alters the
cellular phenotype and influences proliferation and hapto-
taxis [3]. Recently, Radhakrishnan et al. demonstrated the
impact of truncated O-glycans on cell-cell adhesion and
migration in pancreatic cancer [4].
The Tn antigen (GalNAcα1-O-Ser/Thr) is a frequently
occurring aberrant O-glycan expressed at high levels in
many cancers [5] including pancreatic ductal adenocar-
cinoma (PDAC) [6–8], PDAC precursor lesions [7] and
is detectable in PDAC sera [9, 10]. Expression of Tn
antigen and its sialylated form sialyl-Tn (STn) antigen is
associated with poor survival [11, 12] and promotes
oncogenic features [4]. Tn antigen expression is initiated
by polypeptide N-acetylgalactosaminyltransferases (Gal-
NAc-Ts), which connect GalNAc residues with the target
protein as a posttranslational modification. In humans,
20 different GalNAc-Ts are identified so far, leading to a
complex interplay of various enzymes reflected in the
cellular O-glycobiome. Tn antigen is further processed
by core 1 synthase (C1GALT1 or T-synthase), which
transfers Galactose (Gal) to GalNAc-Ser/Thr to form the
T antigen, also referred as core 1 structure. COSMC
(C1GALT1C1) is the unique chaperone of T-synthase
and is essential for its functional formation in order to
elongate glycans beyond the initial Tn structure (Fig. 1a)
[13]. Dysfunctional COSMC is also able to convert a
wild type protein into a tumor-specific antigen [14]
affecting tumor cell biology.
Several factors are known to contribute to the formation
of Tn/STn antigen on glycoproteins. Major factors are al-
tered levels in COSMC and/or T-synthase gene expression
as well as differential expression and localization of
GalNAc-transferases. In detail, acquired mutations in
COSMC [13, 15], epigenetic silencing of COSMC and/or
T-synthase, including hypermethylation of the COSMC
promotor [4, 16] as well as altered signaling pathways and
altered expression or localization of GalNAc-transferases
[17–22] may contribute to Tn and/or STn expression.
Tn/STn antigens are cancer-associated glycans recog-
nized by the human macrophage galactose binding
glycoreceptor MGL (CLEC10A/CD301) [23–25] that is
expressed on immature and tolerogenic dendritic cells
and macrophages. Since Tn/STn glycans and glycopep-
tides are not or poorly immunogenic, vaccination based
cancer therapy remains challenging. Nonetheless, the
attempt of generating Tn specific antibodies with in vivo
anti-tumor activity was described [26, 27]. Preclinical
animal studies showed promising immunogenicity, but
none of the immuno conjugates succeeded in clinical
trials, despite safe administration and proper immune
responses [28]. Recent and ongoing vaccine trials are
encouraging for future trials and the design of proper
immunogens and immuno-conjugates remain the main
challenge. Interestingly, ABO blood group IgM aggluti-
nins/antibodies were observed to interact with PDAC
O-GalNAc modified glycoproteins possibly affecting
cancer onset [29].
Nevertheless, pancreatic carcinoma is one of the worlds’
most aggressive malignancies [30] and consequences of
COSMC mediated Tn antigen expression in pancreatic
carcinoma are not fully understood. Investigation of Tn
modified glycoproteins and its impact on oncogenic prop-
erties is crucial to understand tumor biology and potential
therapeutic options.
Results
Differential expression of Tn antigen in human pancreatic
carcinoma cell lines
Several PDAC derived cell lines were available for Tn
antigen screening using Western and Far-Western blot
analysis. Besides commercially available PDAC cell lines
such as Panc-1, BxPC3, MiaPaca2 and L3.6pl, patient de-
rived cell lines PaCa 5061 [31], PaCa 5072 and PaCa
5167, and a Gemcitabine resistant sub-clone of the par-
ental L3.6pl cell line, L3.6pl-res cells were used [32].
Analysis of Tn antigen expression in cell lysates was per-
formed using distinct antibodies or glyco epitope recog-
nizing lectins. Jurkat cells express mutated COSMC [13]
and were used as Tn antigen positive control. Interest-
ingly, PDAC cell lines displayed differential expression
of the Tn antigen. Using the Tn antigen specific antibody
MA1-90544, L3.6pl-Res and PaCa 5072 cells showed a
strong positivity, whereas L3.6pl, PaCa 5061 and BxPC3
cells were weakly positive. Minimal signals were detect-
able in Panc-1, PaCa 5167 and MiaPaca2 cells (Fig. 1b).
Similar results were obtained using VVL, HPA lectins
and sialyl Tn antibody reflecting consistency (Additional
file 1: Figure S1-S3).
In order to induce the expression of Tn antigen in the
minimal Tn antigen positive Panc-1 cell line and the
moderate Tn antigen positive L3.6pl cell line, we per-
formed a lentiviral-mediated knockdown of COSMC
chaperone followed by single colony selection with puro-
mycin. Knockdown of COSMC was highly efficient in
Panc-1 cells, compared to cells transduced with a control
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vector (Additional file 1: Figure S4). Additionally, down
regulation of COSMC was confirmed on mRNA level by
real-time PCR, achieving 97 % efficiency in Panc-1 and
73 % in L3.6pl cells (Fig. 2b and d). Next, expression of
atypical O-glycans was evaluated using different glyco epi-
tope recognizing antibodies and lectins. Using sialyl-Tn
and Tn antigen antibodies as well as VVL and WFL,
revealed an enhancement of distinct staining patterns in
COSMC knockdown cells compared to control cells
(Fig. 1c). L3.6pl cells revealed an enhanced Tn antigen
expression only after treatment with Neuraminidase
(Additional file 1: Figure S5). Immunocytochemistry
revealed an enhanced staining of VVL and WFL lectin
in COSMC knockdown cells compared to controls
(Additional file 1: Figure S6).
Decreased expression of GalNAc-transferases in COSMC
knockdown cells
COSMC knockdown causes a cell type specific Tn antigen
expression pattern mediated by the subset of expressed
GalNAc-transferases. Since GalNAc-transferase 2 and 5
are already identified as O-GalNAc modified glycoproteins
[33], a COSMC knockdown could influence GalNAc-
transferase activity and consecutive GalNAc-T expression
levels as a cellular response. This could result in an altered
Tn antigen expression pattern caused by impaired
GalNAc-T activity compared to the initially induced
COSMC knockdown Tn antigen expression pattern. Since
GalNAc-transferase activity assays are not available, we
analyzed GalNAc-Ts expression levels in COSMC knock-
down cells compared to controls. We used quantitative
real-time PCR to evaluate expression levels of all known
human GalNAc-Ts (1–20) in Panc-1 as well as L3.6pl
COSMC knockdown cells and corresponding control cells.
In seven out of 20 investigated GalNAc-T isoform mRNAs
were readily detectable using real-time PCR and showed
differential mRNA expression levels in COSMC knock-
down cells. The GalNAc-T isoforms 1, 2, 7, 10, 11, 12, and
18 were expressed in Panc-1 cells (Fig. 2a). Interestingly,
COSMC-depleted Panc-1 cells showed a substantial
decrease in mRNA expression for all detected GalNAc-T
isoforms, compared to the respective control cells. In fact,
relative mRNA expression was decreased up to 50 %
(p <0.001) (Fig. 2a). Also, analysis of mRNA expression
levels of the T synthase, a key enzyme in the cellular
O-glycan pathway, revealed a substantial increase in
COSMC knockdown cells, compared to control cells
(Fig. 2b). L3.6pl cells showed the expression of GalNAc-T
isoforms 1, 2, 3, 7, 10, 11, 12, 14 and 18 (Fig. 2c). Except
GalNAc-T 2, all other isoforms showed decreased mRNA
expression in COSMC knockdown cells, comparable to
the results of Panc-1 COSMC knockdown and control
(Fig. 2c). In contrast, L3.6pl COSMC knockdown was
approximately 80 %, and T-synthase levels did not display
any differences (Fig. 2d). Next, T-synthase activity was
measured in Panc-1 and L3.6pl cells. Panc-1 COSMC
knockdown cells displayed 69.9 % T-synthase activity and
T-synthase activity in L3.6pl COSMC knockdown cells was
67 %, compared to control cells (Fig. 2e).
MS-based identified Nucleolin, GRP-78, α-Enolase and
Annexin A2 display O-GalNAc glycosylation
Although several Tn antigen carrier molecules have been
identified in various cancers, the molecular identity of
these different O-glycosylated proteins still remains en-
igmatic. In order to identify new pancreatic cancer spe-
cific O-glycosylated proteins that express the Tn antigen,
we applied lectin-based immunoprecipitation using VVL
in COSMC knockdown as well as corresponding control
cells (Additional file 1: Figure S7) accompanied by pep-
tide identification via mass spectrometry. VVL is able to
bind glycopeptides through single GalNAc molecules
and its binding affinity was demonstrated to depend on
Tn antigen cluster formation [34].
Among the top hits, we identified Nucleolin, GRP-78,
Annexin A2 and α-Enolase (Tab.1). A careful review of
the literature revealed that Nucleolin and GRP-78 have
previously been described to carry O-glycosylated resi-
dues [33, 35]. These four candidates appeared to be
promising, because these proteins i) are differentially
expressed in pancreatic carcinoma [36–39], ii) are cell
membrane localized (at least in carcinoma) [40–43] iii)
and are known to promote cancer cell signaling. More-
over, in silico analysis of the identified peptide protein
sequences using the isoform specific O-glycosylation
prediction (ISOGlyP) database [44], revealed that these
(See figure on previous page.)
Fig. 1 Expression of aberrant O-glycans in pancreatic cancer. a Biosynthesis of Tn antigen, sTn antigen and Core1 and 3 structures. Tn antigen is
composed of an O-glycosidic linked N-acetylgalactosamine (GalNAc) to the –OH group of serine/threonine (S/T). Tn antigen is either processed
by core 1 T-synthase (C1GalT1) and its chaperone (COSMC), which transfers a galactose (Gal) to GalNAc-serine/threonine to form the T antigen
also referred as core 1 structure or processed by transfer of a N-acetylglucosamine (GlcNAc) to form the core 3 structure. Tn antigen can also be
modified by addition of a sialic acid (NeuAc). b Differential expression of Tn antigen in pancreatic carcinoma cell lines. Eight different PDAC cell
lines were available for analysis. Western and Far-Western blot analysis of total cell lysates was performed using the Tn antigen specific antibody
MA1-80055. Detection of HSC70 served as loading control. Jurkat cells were used as positive control for Tn antigen expression. c Expression of Tn
antigen and aberrant O-glycans in COSMC knockdown cells. Western blot analysis showed a strong expression of aberrant O-glycans as well as
Tn antigen in Panc-1 COSMC knockdown cells compared to control cells. Sialyl-Tn and Tn antibodies were used as well as lectins such as VVL
(Vicia villosa lectin) and WFL (Wisteria floribunda lectin)
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proteins are likely to be O-GalNAc glycosylated [33].
Referring to the results of GalNAc-transferase isoform
expression of Panc-1 cells, isoforms T1 and T12 showed
highest prediction possibility of O-GalNAc-glycosylation
for Nucleolin. Highest prediction for GRP-78 showed
GalNAc-transferase isoforms T2 and T12, for α-Enolase
T10 and T12 and for Annexin A2 T1 and T2.
For proof-of-concept, we confirmed the Tn expression
on Nucleolin, GRP-78, α-Enolase and Annexin A2
through VVL-based immunoprecipitation followed by
detection of the target proteins with specific antibodies
(Fig. 3a). Protein expression levels of the identified
proteins in total cell lysates of COSMC knockdown as well
as control cells remained unchanged, except for Annexin
A2 which showed a decrease in Panc-1 COSMC knock-
down cells (Fig. 3a). Vice versa immunoprecipitation with
the protein specific antibody and detection with VVL lectin
showed distinct staining patterns at indicated molecular
weight (Fig. 3b). Additionally, we performed immunocyto-
chemistry to investigate the intracellular localization of Tn
antigen and Nucleolin using COSMC depleted Panc-1 cells.
Interestingly, VVL mediated Tn antigen staining showed
cell surface as well as a predominant cytoplasmic staining.
The co-staining of Nucleolin in COSMC knockout Panc-1
(See figure on previous page.)
Fig. 2 Aberrant mRNA expression levels of GalNAc-transferases, T-Synthase and COSMC as well as T-synthase activity in COSMC-depleted pancreatic
cancer cells. a Relative mRNA expression of all human GalNAc-transferase isoforms in COSMC knockdown as well as control Panc-1 cells, quantified
using real-time PCR. b Relative quantification of T-synthase mRNA expression in COSMC knockdown and control Panc-1 cells. Note: mRNA expression
level of T-synthase is almost doubled in COSMC knockdown cells. c Relative mRNA expression of GalNAc-transferase isoforms in L3.6pl. d Relative
quantification of T-synthase and COSMC mRNA expression in L3.6pl COSMC knockdown and control cells. e T-synthase activity was measured in
Panc-1 and L3.6pl COSMC knockdown and control cells using GalNAc-α-4MU fluorescent assay
Table 1 Mass spectrometry identified O-GalNAc modified proteins
Protein Gene Uniprot acc. No. NetOGlyc 4.0 References
Nucleolin NCL P19338 +++ [35]
Alpha-1-acid glycoprotein 1 AGP1 P02763 -
Alpha-actinin-4 ACTN4 O43707 +++
Ig alpha-1 chain C IGHA1 P01876 ++
Elongation factor 2 EEF2 P13639 ++
GRP-78 HSPA5 P11021 + [33]
HSP73 HSPA8 P11142 +
PABP1 PABPC1 P11940 ++
PABP4 PABPC4 Q13310 +
Alpha-enolase ENO1 Q6GMP2 +
Elongation factor 1-gamma EEF1G P26641 ++
EF-1-alpha-like 3 EEF1A1P5 Q5VTE0 +
Tubulin beta TUBB2A Q13885 -
Galectin-12 LGALS12 Q96DT0 ++
Ras association domain-containing protein 2 RASSF2 P50749 +++
GAPDH GAPDH P04406 +
Nucleophosmin NPM1 Q8WTW5 +++
Annexin A2 ANXA2 P07355 +
37 kDa laminin receptor precursor RPSA Q86VC0 +++
Leucyl-cystinyl aminopeptidase LNPEP Q9UIQ6 +
eIF-5B EIF5B O60841 +++
Armadillo repeat-containing protein 4 ARMC4 Q5T2S8 +++
LanC-like protein 2 LANCL2 Q9NS86 ++
Proteins identified from Panc-1 COSMC knockdown cells by immunoprecipitation using VVL agarose accompanied by mass spectrometry. The O-GalNAc prediction tool
(NetOGlyc 4.0) [52] was used to assess possibility of O-glycosylation. Score indicates percentage of possibly O-GalNAc modified Serin/Threonin residues (+ <10 %, ++ <20 %,
+++ > 20 %). References are presented for previously identified O-GalNAc modified glycoproteins





































































Fig. 3 MS identified Nucleolin, GRP-78, α-Enolase and Annexin A2 display O-GalNAc glycosylation. a left: Tn antigen is expressed on Nucleolin,
GRP-78, α-Enolase and Annexin A2. Immunoprecipitation and western blot analysis were performed using VVL lectin for Tn antigen precipitation
and Nucleolin, GRP-78, α-Enolase and Annexin A2 antibodies for detection of specific protein signals. a right: Protein expression levels of the
identified proteins in total cell lysates of COSMC knockdown as well as control cells remained unchanged, except for Annexin 2, which showed a
decrease in Panc-1 COSMC knockdown cells. b Vice versa, immunoprecipitation using specific antibodies and detection with VVL lectin was
performed as well. c Immunocytochemistry of Panc-1 COSMC knockdown cells and control cells. Left: Aberrant O-glycans, including Tn antigen,
were detected using VVL-FITC conjugated lectin (green). Middle left: Nucleolin was detected (red) using an anti-Nucleolin antibody (ab13541).
Middle right: Nuclei were stained with DAPI (blue). Right: Overlay of Tn antigen and Nucleolin immunocytochemistry. d Nucleolin, GRP-78, Enolase
and Annexin detection in the cell membrane protein fraction. Her2 antibody was used as marker for membrane fraction and GAPDH antibody
was used as marker for cytoplasmic proteins
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cells revealed also cell membrane localization and a nu-
clear/perinuclear staining. Co-staining of Tn antigen and
Nucleolin in COSMC knockdown cells revealed strong co-
localization. Panc-1 control cells showed a perinuclear
staining of Nucleolin and VVL. Altogether the staining of
Panc-1 control cells was much weaker compared to Panc-1
COSMC knockdown cells (Fig. 3c).
Previously, it was shown that two of the newly identi-
fied Tn antigen carrier proteins, Nucleolin and GRP-78
also localize at the plasma membrane [45, 46]. There-
fore, we separated membrane-bound and cytosolic pro-
teins of Panc-1 COSMC knockdown cells and control
cells. Western blot analysis revealed that Nucleolin and
GRP78 are membrane localized in pancreatic cancer cells,
confirming previous findings. Furthermore, Annexin A2
and α-Enolase were also detected in membrane protein
fractions of Panc-1 COSMC knockdown cells and control
cells. Successful cellular fractionation was confirmed using
antibodies targeting Her2 and GAPDH (Fig. 3d).
COSMC knockdown promotes migration and survival and
inhibits proliferation in PDAC cells in vitro.
To gain relevant insights into COSMC function in pan-
creatic cancer cells, we first analyzed whether COSMC
might influence proliferation of Panc-1 cells. Interest-
ingly, analysis of Panc-1 COSMC knockdown cells by
MTT assay revealed a strong reduction in proliferation,
compared to control cells (p <0.001), whereas COSMC
knockdown had no effect on proliferation in L3.6pl cells
(Fig. 4a). Next, we analyzed the influence of COSMC
expression on cancer cell migration in vitro. Therefore,
we performed transwell assays and quantified the migra-
tory potential of COSMC knockdown as well as corre-
sponding control cells after 24 h. Migration of Panc-1
COSMC knockdown cells was substantially higher com-
pared to control cells (Fig. 4b-c) (p < 0.001). Additionally,
migrating cells were recorded in a wound healing assay
and the cell displacement rate during migration was
quantified. The median displacement rate of Panc-1
COSMC knockdown cells was 154.4 μm/s whereas control
cells showed a median displacement rate of 108.1 μm/s
(p <0.05). The displacement rate of Panc-1 COSMC
knockdown cells was 0.00153 μm/s and that of Panc-1
control cells was 0.00095 μm/s (p <0.05) (representative
images are shown in Fig. 4b). The meandering index of
Panc-1 COSMC knockdown cells was 0.261 and 0.196 in
control cells (p <0.001). To analyze whether COSMC
knockdown influences apoptosis in pancreatic cancer, a
cleaved Caspase-3 ELISA assay was performed. Interest-
ingly, COSMC depleted Panc-1 and L3.6pl cells showed
substantially decreased apoptosis compared to corre-
sponding control cells. Cleaved Caspase-3 expression was
determined after 24 h and showed a 53 % reduced apop-
tosis rate in Panc-1 COSMC knockdown cells (p =0.03).
L3.6pl COSMC knockdown cells showed a 44 % reduction
of apoptosis rate (p =0.017) compared to control (Fig. 4d).
Tn antigen and Nucleolin are frequently co-localized in
PDAC patient specimens
It is well known that non-malignant epithelial cells display
long branched O-linked glycan structures such as core 2
and core 3 glycans that are attached, for instance to
various mucins [47]. In malignant cells, a complex inter-
play of various glycosyltransferases/chaperones promotes
a reduced expression of long branched glycans and con-
comitant increase truncated glycans (Tn antigen).
To analyze whether pancreatic cancer cells display
such truncated glycans on the MS-based identified
Nucleolin, we analyzed 43 different PDAC patient speci-
mens using VVL-mediated detection of Tn antigen and
its possible co-localization with Nucleolin using specific
antibodies. To exclude possible cross-reactivity of VVL
with other blood group determinants (A and AB) [29],
we solely analyzed PDAC specimens derived from non-
A and non-AB blood group patients. The degree of Tn
expression and Nucleolin expression partially reflects the
degree of co-localization. In fact, co-localization was deter-
mined in 3 groups: 1. Tn/Nucleolin expression and co-
localization, 2. Tn/Nucleolin expression without/minimal
co-localization, 3. Minimal Tn/Nucleolin expression
without/minimal co-localization. Group 1 was compared
to group 2/3 and named strong co-localization vs. weak
co-localization. Interestingly, immunofluorescence stain-
ing of these tumor specimens showed tumors with weak
or strong co-localization of Tn antigen and Nucleolin
(Fig. 5a). 22 (51 %) PDAC specimens showed weak and 21
(49 %) PDAC specimens showed strong co-localization.
Moreover, correlation of this co-localization with available
clinical survival data revealed poor survival for patients
with a strong co-localization compared to patients with a
weak co-localization of Nucleolin and VVL in Kaplan-
Meyer survival analysis using Log-Rank test (p = 0.037).
Five patients in the group of weak co-localization and one
patient with strong co-localization of Tn antigen and
Nucleolin were censored, because they outlived the
1500 days follow up periode (Fig. 5b). In our study, the
degree of Tn antigen and Nucleolin expression is not
related to survival of patients suffering pancreatic ductal
adenocarcinoma (log-rank test, p = 0.95 and p = 0.34)
(Additional file 1: Figure S10 and S11).
Discussion
The discovery of Tn antigen was a milestone in the history
of glycosciences [5]. The Tn antigen was first described in
the Tn polyagglutination syndrome by Moreau et al. in a
patient with hemolytic anemia [48]. The underlying mech-
anism was discovered 48 years later in 2005 by Ju and
Cummings and was identified as a mutation of the
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COSMC chaperone [49]. Since then, functional studies
with expression of Tn antigen via manipulation of
COSMC chaperone was possible and the knowledge on
differential cancer O-glycosylation was greatly expanded.
In this study, we examined different pancreatic cancer
cell lines to give an overview of Tn antigen expression
and to determine cell lines with low or moderate Tn
antigen expression. We detected high molecular weight
signals (150–250 kDa), indicating detection of high mo-
lecular weight proteins similar to the known mucin
staining, but the Jurkat control cell line showed strong
signals of lower molecular weight bands with approxi-
mately 75 kDa. On the other hand, lectins showed cell
line dependent staining over a broad range with molecu-
lar weights between <50 - 250 kDa. These detected dif-
ferences are probably due to varying binding specificity
of different lectins and antibodies regarding the amino
acid back bone of Tn antigen carrying proteins [50]. In
addition, the detected Western blot signals are probably
not solely Tn antigen expression but also a staining of
terminal presented GalNAc structures [17–22, 51]. One
way of Tn antigen expression in human carcinoma cells is
the loss of functional COSMC. Tn antigen expression has
been shown in cervical carcinoma, melanoma and colon
carcinoma cells due to somatic mutation of COSMC or
absence of COSMC transcript [15]. Epigentic silencing
through methylation of COSMC promotor in pancreatic
carcinoma caused inactivation of T-synthase with
consecutive aberrant O-glycosylation [4]. In this study,
we investigated the influence of Tn antigen expression
on pancreatic carcinoma cells using a stable lentiviral-
mediated COSMC knockdown and detected an enrichment






















Panc-1 COSMC knock down 
Panc-1 control 







Fig. 4 COSMC knockdown promotes migration and survival and inhibits proliferation in PDAC cells in vitro a Proliferation of Panc-1 COSMC
knockdown cells compared to control. Proliferation was measured in MTT assay over 96 h using Panc-1 COSMC knockdown cells (black) and
control cells (grey) (p < 0.001). L3.6pl COSMC knockdown and control cells are indicated as dotted line. b above: Scratch assay are displayed for
Panc-1 COSMC knockdown cells compared to control at different time points. b below: HE stained transwell membranes after 24 h of Panc-1
COSMC knockdown cells (left) and control cells (right) c: Relative migration of Panc-1 and L3.6pl COSMC knockdown cells was compared to
control cells using transwell assay. Migrated cells were determined after 24 h (p≤ 0.001). d: Apoptosis rate of Panc-1 and L3.6pl COSMC
knockdown cells was compared to control cells using ELISA based cleaved Caspase-3 assay. Cleaved Caspase-3 expression was determined
after 24 h (p = 0.03 and 0 = 0.017)
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Since GalNAc-transferases (GalNAc-Ts) catalyze the
first step of O-glycosylation which results in the forma-
tion of Tn antigen, we also examined whether COSMC
knockdown influences expression levels of all known
human GalNAc-Ts. Interestingly, we detected substan-
tially decreased mRNA levels for various GalNAc-Ts in
COSMC knockdown cells. Down-regulation of GalNAc-
T mRNA expression after COSMC knockdown might
indicate a negative feedback regulation, which reduces
the expression of GalNAc-T mRNA in the presence of
elevated Tn antigen levels. This might represent a novel
mechanism of regulation for the activity of GalNAc-Ts,
since the activity of GalNAc-Ts is known to be regulated
through expression levels or by regulated relocation of
GalNAc-Ts from Golgi apparatus to endoplasmic
reticulum [18]. Analyzing the obtained expression results
of GalNAc-Ts, we can state with certainty, that the ob-
served changes in O-glycosylation are COSMC knock-
down mediated. In contrast, T-synthase mRNA expression
levels increased 2-fold in COSMC knockdown cells com-
pared to control cells. The increased T-synthase levels
might be an attempt of the cell to overcome the lack of
functional T-synthase.
Using mass spectrometry, we identified 23 different O-
GalNAc glycosylated and abundantly expressed proteins
in Panc-1 COSMC knockdown cells. Mapping of the
human O-GalNAc glycoproteome has recently gained
great importance using a zinc finger nuclease mediated
targeting of COSMC gene [52]. Amongst several cell
lines, this technology was also used in Capan-1, a
Fig. 5 Tn antigen and Nucleolin are frequently co-localized in PDAC patient specimens. a Tn antigen and Nucleolin expression in PDAC.
Immunohistochemistry of patient-derived PDAC samples revealed a frequent co-expression (orange) of Tn antigen using VVL-mediated staining
(green) and Nucleolin staining (red). Nuclei were detected with DAPI (blue). Pictures marked with + displayed a tumor specimen with strong
co-expression, whereas the tumor probe marked with – showed weak co-expression b Kaplan-Meyer survival plot with 43 PDAC patients with
strong and weak co-localization of VVL and Nucleolin staining (p = 0.037)
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pancreatic cancer cell line. The authors found that al-
most 50 % of the identified glycoproteins were expressed
uniquely in one cell line and each cell line contributed
its own repertoire of glycoproteins. Altogether only 14
proteins were identified in all 12 cell lines and a new
subset of glycoproteins was found [52]. These findings
suggest distinct O-glycoproteomes for each type of
cancer, however, further investigations are needed to
gain insights into its possible therapeutic value.
Targeting of tumor specific O-glycoslyation is a prom-
ising treatment strategy for cancer, but faces various
challenges. After Tn antigen administration, a sufficient
immune and anti-tumor response in nonhuman pri-
mates was induced [53]. Thereafter, Tn antigen evolved
to an important component of glycoconjugate based
anti-tumor vaccines [5, 54]. Springer and colleagues re-
ported a successful vaccination of 16 breast cancer
patients with a statistical significant better survival, how-
ever, the validity of their data cannot be determined due to
the absence of several controls as well as appliance of a
questionable glycoprotein preparation [55]. The treatment
of prostate cancer was another focus of Tn antigen based
vaccination. In a phase I clinical trial, all patients devel-
oped an immune response against Tn antigen, but only
33 % achieved favorable clinical responses with decreased
detection of prostate-specific antigen [56]. Long-term sur-
vival data have not been published so far, but these studies
might provide a first prospect whether Tn antigen vaccin-
ation results in favorable effects in patients. Nonetheless,
to provide a substantiate basis for successful vaccination
with Tn antigen, a proper antigen expression is required.
Since the first discovery of Tn antigen, a variety of
methods have been developed, mostly being dependent
on either antibodies or lectins. A high number of differ-
ent GalNAc-binding lectins or antibodies are available
and were already successfully applied in various expres-
sion studies of human cancers, including pancreatic
cancer. Unfortunately, the results of these studies
showed no consistency, which might be a consequence
of different binding specificities of individually used lectins
and antibodies. Tn antigen binding lectins and antibodies
may also cross-react with other carbohydrate antigens
[51]. In addition, monoclonal antibodies recognize not
only the Tn antigen but also depend on the individual
amino acid backbone of the protein, leading to a distinct
recognition pattern of Tn containing glycoproteins on
cancer cells [50].
Altogether, pancreatic cancer has most likely its spe-
cific glycoproteome and hence the need arises for its
specific detection. Here, we focused on the identification
of aberrant O-glycosylated proteins in pancreatic cancer.
The proteins identified may contribute to a better un-
derstanding of the pancreatic cancer O-glycoproteome
and may help to develop pancreatic cancer specific
vaccinations or other therapies in future. Therefore,
membrane-associated proteins were of pivotal interest,
because they represent potential targets for immuno-
therapy. We evaluated all 23 O-glycoproteins regarding
their localization in cancer, involvement in signal trans-
duction and focused our analysis on four proteins for
further characterization (Tab. 1). In this study, Tn anti-
gen expression was confirmed for Nucleolin, GRP-78,
Enolase and Annexin A2 using a VVL-based immuno-
precipitation and all other identified Tn antigen carrier
proteins were predicted to be highly O-glycosylated by
the ISOGlyP database. Moreover, we could clearly show
that Nucleolin is frequently co-localized with Tn antigen
in patient-derived PDACs and strong co-localization is
correlated with poor survival of the patients.
Additionally, the degree of Tn and Nucleolin expres-
sion is not related to survival of patients suffering from
pancreatic ductal adenocarcinoma (log-rank test)
(Additional file 1: Figure S8 and S9). To the best of our
knowledge, the relation of Tn expression to survival was
only reported for endometrial, colon and breast cancer
[47, 57]. The lack of correlation in pancreatic cancer is dif-
ficult to explain and is possibly caused by the biologic na-
ture of pancreatic cancer characterized by an extremely
rapid tumor progression. Therefore, the survival of
patients is generally very short and an influence of Tn
antigen expression on survival is possibly masked.
Furthermore, information regarding the biological ef-
fects of COSMC knockdown on cell growth, migration
and apoptosis in pancreatic cancer is scarce. Interest-
ingly, our analysis of COSMC knockdown cells revealed
an enhanced migration and decreased apoptosis accom-
panied by reduced proliferation compared to control cells
in vitro. In breast cancer cells, implications of sialyl-Tn
antigen on adhesion, migration, proliferation and tumor
growth were already investigated and showed an enhanced
tumorigenesis [58, 59]. Recently, Huang et al. detected an
enhanced malignant behavior of colon cancer cells over-
expressing COSMC chaperone [60], equivalent to our ana-
lysis of PDAC specimens, which showed an increased
expression of COSMC and T-synthase (Additional file 1:
Figure S10 and S11). Due to the large proportion of
stromal tissue in PDAC, the obtained regulations in gene
expression need not necessarily reflect the actual situation
in cancer cells. Although in contrast to our findings, both
overexpression and COSMC knockdown may lead to an
enhanced expression of aberrant O-glycans and therefore
contribute to the same malignant behavior of tumor cells.
We also analyzed Tn antigen and Nucleolin expression
in pancreatic cancer specimens and found a poor sur-
vival of patients with strong co-localization of Nucleolin
and VVL staining, which may suggest a new role of ab-
errant O-glycosylated proteins as biomarkers. Many of
the current clinical biomarkers display carbohydrate
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modifications, but their basis and precise structure are
largely not understood, because of their molecular com-
plexity and their unknown regulations [61].
Conclusion
In conclusion, our study demonstrates the influence of
altered O-glycan (Tn/STn) expression on oncogenic
properties in pancreatic cancer and identifies O-GalNAc
modified Nucleolin as novel prognostic marker.
Material and methods
Cell culture
Panc-1, HEK-293 T, BxPC1 and MiaPaCa 2 cell lines were
maintained in DMEM and L3.6pl were maintained in
RPMI, each supplemented with 10 % (v/v) FCS, and 1 %
(v/v) penicillin and streptomycin. Patient derived cell
lines 5061, 5072 and 5167 were maintained in RPMI
1640 with Glutamax (Life Technologies) supplemented
with 10 % of fetal calf serum (FCS), 200 IU/ml of penicillin-
streptomycin, 0.1 mg/ml gentamycin (Biochrom), 50 nmol/ml
of human transferrin (Sigma-Aldrich), 0.01 μg/ml of
bovine insulin (Sigma-Aldrich), 0.01 μg/ml of recom-
binant human epidermal growth factor (Pepro Tech),
and 0.01 μg/ml of human basic fibroblast growth
factor (Pepro Tech).
Cells were cultured at 37 °C in a humidified atmos-
phere containing 5 % CO2. All cell lines were used at
low passage number not exceeding 30 passages.
Western blot analysis and antibodies/lectins
Total protein concentrations were measured using BCA
Protein Assay (Thermo Fischer). Samples containing
30 μg total amount of protein were boiled for 5 min in
Laemmli buffer and separated by SDS PAGE under
reducing conditions in 4-15 % Mini-PROTEAN TGX
gels (BIO-RAD). Proteins were blotted on nitrocellulose
membrane (Thermo Fischer). The membrane was
blocked with 1x Carbo-Free Blocking Solution (Biozol)
in TBS-T and subsequently incubated with serum (1:20)
in TBS-T overnight. Tn antigen antibody (MA1-80055,
clone BRIC111, Thermo Fischer), sTn antigen antibody
(ABIN356328, clone STN218, antibodies online) and
COSMC antibody (19254-1-AP, Proteintech) were
diluted 1:250 in TBS-T. HSC70 (sc-7298), GAPDH
(sc-32233,) Nucleolin (sc-8031), GRP78 (sc-1051), Alpha
Enolase (sc-7455) and Annexin II (sc-9061) antibodies
were purchased from Santa Cruz and diluted 1:1000.
Her2 antibody (#2165, Cell Signaling) was diluted 1:100.
Vicia villosa lectin B4 (B-1235) (VVL) and Wisteria
floribunda lectin (B-1355) (WFL) were purchased from
Vector Laboratories and diluted 1:125. Washing was
performed 5 times with TBS-T. The membrane was
incubated with a specific HRP-antibody (1:1250; Life
Technologies) for 1 h at RT. After 5 times washing with
TBS-T buffer, immunodetection was performed using
enhanced chemiluminescence (GE Healthcare). Protein
expression was quantified using an LAS-3000 Imager
from Fuji (Raytest, Straubenhardt, Germany).
Lentiviral-mediated knockdown of COSMC chaperone
pLKO.1-puro vector encoding COSMC and non-target
(scrambled, SCR) shRNA were purchased from Sigma-
Aldrich (Germany). Generation of pseudotyped lentivi-
ruses and transduction were performed as previously
described [62]. Cells transduced with COSMC shRNA
were selected by addition of puromycin (Sigma-Aldrich)
to culture medium with a final concentration of 2 mM
for at least one week.
Immunoprecipitation and membrane protein extraction
Total cell lysates were prepared with RIPA buffer. Ly-
sates (0,5 mg) were pre-cleared with 40 μl of protein A/
G-agarose beads (Santa Cruz) for 1 h. Protein A/G-agar-
ose beads were added to the afore mentioned antibodies
and rotated at 4 °C 1 h. Pre-cleared proteins and bead-
conjugated antibodies were mixed, rotated at 4 °C over-
night, pelleted and washed five times with RIPA buffer.
An equal volume of 6xLaemmli buffer was added, and
samples were boiled and separated by SDS–polyacryl-
amide gel electrophoresis. For membrane protein extrac-
tion, harvested cells were resuspended in PBS and
homogenized using a dounce homogenizer. Centrifugation
at 100 g, 5 min, 4 °C removed undisrupted cells a second
centrifugation at 100 g, 10 min, 4 °C extracted nuclei.
After centrifugation at 20000 g for 90 min, at 4 °C, mem-
branes were pelleted and the supernatant contained the
post membrane fraction.
Real-time PCR
Total RNA was isolated using the RNeasy Mini kit
(Qiagen), reverse transcribed with Transcriptor reverse
transcriptase (Roche) using an oligo-(dT) primer accord-
ing to the manufacturer’s protocol. The cDNA was sub-
jected to real-time PCR amplification using primer sets for
COSMC, GalNAc-transferases, T-synthase and GAPDH
(Additional file 2: Table S1). Real-time PCR was prepared
with Maxima SYBR Green/ROX qPCR Master Mix,
0.3 μM forward and reverse primer and 750 ng cDNA and
used on the Lightcycler 480 (Roche). The conditions were
as follows: 95 °C for 10 min, 45 cycles at 95 °C for 15 s,
and 60 °C for 1 min. CT values were determined using
Lightcycler 480 Software version 1.5 (Roche). All samples
were analyzed in duplicates, and values of the sample
copies were obtained after quantitative amplification and
normalized to GAPDH using 2−ΔΔCT method. Each
experiment was at least repeated twice.
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Mass spectrometry (MS)
O-GalNAc modified proteins were identified by MALDI-
MS. Protein bands were excised from Coomassie stained
polyacrylamide gel and trypsin (sequencing grade,
Promega) was added to each sample for 4 h at 37 °C.
Extracted peptides were mixed with the matrix solution
containing α-cyano-4-hydroxycinnamic acid, spotted for
MALDI-MS measurement onto target slides, and analyzed
using a matrix-assisted laser desorption/ionization time
of flight (MALDI-TOF) mass spectrometer (Amersham
Biosciences). All measurements were performed in the
positive-ion reflective mode at an accelerating voltage of
23 kV and delayed-pulsed ion extraction. All peptide sam-
ples were measured as monoisotopic masses. Database
searches were performed using the MASCOT software
from Matrix Science with carboxymethylation of cysteine
and methionine oxidations as variable modifications
(probability value p <0.05).
T-Synthase assay
Ten μg total protein from fresh cell lysates were directly
used to determine endogenous T-synthase activity using
UDP-Gal (Sigma Aldrich) as the donor and GalNAc-α-
(4-MU) (Carbosynth) as the acceptor [63]. O-Glycosidase
(New England Biolabs) was used for T antigen cleavage
and release of fluorescent 4-MU. The 50 μL reaction sys-
tem containing 1000 μM GalNAc-α-4-(MU), 500 μM
UDP-Gal, 20 mM MnCl2, 0.2 % Triton X-100, 800 units
of O-glycosidase, in 50 mM MES-NaOH buffer (pH 6.8),
and 10 μg total protein was placed in a black OptiPlate-
96 F (Perkin Elmer). Adding 100 μl 1 M Glycine NaOH
(pH10) stopped reactions. Relative 4-MU fluorescence was
measured (ex 355 nm/em 460 nm) in a FLUOstar Omega
(BMG Labtech). The average value of the fluorescence
intensities was calculated and the control cell line was set
to 100 %. Error bars represent SEM.
Proliferation, migration and apoptosis
The MTT assay was used for determination of cell pro-
liferation. Cells were washed with PBS and MTT (Sigma)
working solution was added into the wells. Cells were in-
cubated at 37 ° C for 2 h. Absorbance of the converted
MTT dye was measured at a wavelength of 490 nm with
FLUOstar Omega (BMG Labtech).
Cell migration was examined using transwell assay and
scratch/wound healing assay. Briefly, 5 × 105/mL cells
were seeded onto a transwell insert (8-μm pore; BD
Biosciences) using DMEM containing 0,1 % FBS. The fit-
ted culture dishes were filled with DMEM containing
10 % FBS. Invaded cells were either stained after 24 h
followed by four random views and quantification under
a microscope or trypsinized and then quantified. For
scratch assay, the corresponding cells were cultured to
create a confluent monolayer. This monolayer was then
scraped with a 200 μl pipet tip to create a “scratch” and
wells were rinsed. The plate was then transferred a
humidified incubation chamber, and cell migration was
recorded using an Improvision LiveCell Spinning Disk
system. Migrating cells were then tracked using Velocity
6.1.1. to quantify the respective cell displacement rate.
Cell death was measured using Cleaved Caspase-3 sand-
wich ELISA (Cell Signaling) according to the manufac-
turer. Each experiment was repeated at least three times
in quadruplicates.
Immunofluorescence
Cells were cultured on coverslips, fixed with 4 % formalde-
hyde for 10 min, washed with PBS and afterwards blocked
for 1 h in 1 % BSA/PBS-T at RT. The cells were then incu-
bated with the primary antibody (Nucleolin 4E2, Abcam)
over night (4 °C) or lectin (VVL-FITC, Vector) for 1 h at
RT and washed with PBS. After incubation with the pri-
mary antibody, a fluorescent secondary antibody (Alexa
Fluor 546 rabbit anti mouse IgG, Life Technologies) was
added for 1 h at RT. After washing with PBS, the speci-
mens were observed under a fluorescence microscope
(BIOREVO BZ-9000; Keyence) and analyzed with BZ-
9000 Generation II Analyzer software.
Statistical analysis
Student’s t-Test (unpaired, 2-tailed) was calculated based
on the data of at least three independent experiments. Bon-
ferroni correction for multiple testing was performed where
applicable. Results were considered significant if p <0.05.
All error bars represent SD, unless indicated otherwise.
Statistical survival analysis was performed using Kaplan-
Meyer method. The differences between survival curves
were tested using log rank test, p <0.05 was considered
significant.
Additional files
Additional file 1: Figure S1-S11. Differential expression of Tn antigen
in human pancreatic carcinoma cell lines. Eight PDAC cell lines were
available for analysis. Western blot was performed using HPA lectin
(Fig. S1), VVL lectin (Fig. S2) and sialyl Tn antibody MA1-90577 (Fig. S3).
HSC70 Western blot served as loading control. Jurkat cell line was used as
positive control for Tn antigen expression. Figure S4: Lentiviral-mediated
COSMC knockdown in Panc-1 cells. Western blotting total cell lysates of
COSMC knockdown and corresponding control cells revealed successful
down regulation of COSMC. HSC70 was used as loading control. Figure S5:
Proteins of L3.6pl COSMC knockdown and control cells were used for
Western blot with (right) and without (left) Neuraminidase treatment.
Neuraminidase treated knockdown cells showed an enhanced Tn
antigen signal, detected with VVL lectin, compared to controls. Figure
S6: Immunocytochemistry was performed using VVL (green) and HPA
(red) lectin for COSMC knockdown cells and control cells. Cell nuclei
were counterstained using DAPI (blue). Figure S7: Distinct enrichment of
aberrant O-glycans in Panc-1 COSMC knockdown cells. Protein precipitation
with VVL lectin was performed. Precipitated proteins containing glyco
epitopes were separated using SDS-PAGE and stained with Coomassie
brilliant blue. Arrows indicate the further analyzed protein bands. Molecular
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weight is indicated in kDa. Figure S8 and S9: Kaplan-Meier survival
estimation was calculated for patients with weak and strong Tn
antigen expression (Fig. S8) and weak and strong Nucleolin expression
(Fig. S9). No statistical differences were detected in both analyses
(p = 0.95 and p = 0.34) using log-rank test. Figure S10: mRNA
expression of COSMC and T-synthase in tumor (black bar) and control
samples (white bar). Average Ct value for COSMC mRNA expression
was 2.8 (±3.45) in PDACs and 5.24 (±1.27) in controls (p = 0.057).
T-synthase expression levels showed an average Ct value of 4.8 (±2.45)
in PDACs and 7.26 (±1.52) in controls (p = 0.015). ddCt values. Figure
S11: Fold change of COSMC and T-synthase mRNA expression of
tumor samples compared to controls are displayed, using the ΔΔCt
method. Majority of the samples showed increased expression levels
of analyzed genes in tumors compared to control.
Additional file 2: Table S1. Real time PCR primer. Primer were
designed using either Primer3 web interface [64] or taken from the
Harvard PrimerBank [65].
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